Grant: Doctoral: Vanier Canada Graduate Scholarships
McMaster University
$150,000.00
Improved Cancer Immunotherapy for Breast Tumours
FY 2017-18
Summary
Breast cancer is a disease that accounts for almost one quarter of all cancers in women. Though current treatment regimens have shown success with early stage primary tumors, there are few to no treatments that can successfully treat aggressive forms, prevent metastasis or completely cure advanced metastatic disease. Triple-negative breast cancer (TNBC) (a subtype negative for hormonal biomarkers) holds an overall dismal clinical outcome due to lack of expression of targets for therapy and as such, patients routinely undergo aggressive regimens of chemotherapy. These regimens come with a multitude of side effects, including high levels of toxicity and an increased risk of developing other forms of cancer later in life.
Immunotherapy, a form of therapy that boosts the immune system to fight cancer cells, has gained increasing prominence in recent years largely due to its safety and astonishing success rates. Some chemotherapies can be classified as immunotherapies when administered at low doses, as they stimulate the immune system. Checkpoint blockade is another form of immunotherapy that uses antibodies to initiate the death of cancer cells. It is clinically approved for various forms of cancer and has become a first line treatment for melanoma. Oncolytic viruses (OVs) are another promising form of immunotherapy that selectively kill cancer cells, showing little to no toxicity in healthy cells. They have exhibited excellent clinical tolerability, even when used at high viral doses.
For our work, we propose to exploit and improve upon accumulating clinical knowledge in the development of immunotherapies for TNBC. The proposed studies will focus on clinical relevance and translation in order to generate a new treatment regime that displays minimal toxicity and simultaneously exerts anticancer effects on both primary and metastatic lesions. Although this proposal is specific to breast cancer, the underlying concepts can be applied to many other forms of cancer.
Department
Program
Doctoral: Vanier Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
376104
Name
Vito Alyssa R
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Vanier Canada Graduate Scholarships CIHR
Projecttitle
Improved Cancer Immunotherapy for Breast Tumours
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
Doctoral: Vanier Canada Graduate Scholarships
Keyworddelim
Breast Cancer; Cancer; Cancer Therapy; Immunotherapy; Oncology; Oncolytic Viruses; Virology; Virotherapy
Abstract
Breast cancer is a disease that accounts for almost one quarter of all cancers in women. Though current treatment regimens have shown success with early stage primary tumors, there are few to no treatments that can successfully treat aggressive forms, prevent metastasis or completely cure advanced metastatic disease. Triple-negative breast cancer (TNBC) (a subtype negative for hormonal biomarkers) holds an overall dismal clinical outcome due to lack of expression of targets for therapy and as such, patients routinely undergo aggressive regimens of chemotherapy. These regimens come with a multitude of side effects, including high levels of toxicity and an increased risk of developing other forms of cancer later in life.
Immunotherapy, a form of therapy that boosts the immune system to fight cancer cells, has gained increasing prominence in recent years largely due to its safety and astonishing success rates. Some chemotherapies can be classified as immunotherapies when administered at low doses, as they stimulate the immune system. Checkpoint blockade is another form of immunotherapy that uses antibodies to initiate the death of cancer cells. It is clinically approved for various forms of cancer and has become a first line treatment for melanoma. Oncolytic viruses (OVs) are another promising form of immunotherapy that selectively kill cancer cells, showing little to no toxicity in healthy cells. They have exhibited excellent clinical tolerability, even when used at high viral doses.
For our work, we propose to exploit and improve upon accumulating clinical knowledge in the development of immunotherapies for TNBC. The proposed studies will focus on clinical relevance and translation in order to generate a new treatment regime that displays minimal toxicity and simultaneously exerts anticancer effects on both primary and metastatic lesions. Although this proposal is specific to breast cancer, the underlying concepts can be applied to many other forms of cancer.
Competitiondate
201711
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Vito, Alyssa R
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~